The domestic cardiac pacing production line 27, which is in line with the international advanced level, was completed in Shanghai Zhangjiang Hi-Tech Park. This means that in the near future, China is expected to change the monopoly of imported pacemakers and make more patients cost-effective. Domestic products. Implantation of a cardiac pacemaker is an effective method for treating bradycardia and is widely used internationally. Among the 1.3 billion people in China, 540,000 sudden cardiac deaths and more than 600,000 bradycardia patients need implanted devices, including pacemakers. However, China has not yet fully grasped the core technology of cardiac pacemakers and lack of industrialization experience. The products are almost completely dependent on imports, and the expensive prices have discouraged many patients. "Statistics show that the number of pacemakers used per million people in China is 38, compared with 800 in developed countries, which is less than 1/20 of the latter." Director of the Chinese Medical Association's Heart Rhythm Committee, Beijing Zhang Wei, a professor at the Department of Cardiovascular Diseases, said. Dr. Chang Zhaohua, the investor of the domestic cardiac pacing production line and the chairman of Shanghai MicroPort Medical , told the author that the completed domestic cardiac pacing production line was jointly invested by MicroPort Medical and the Italian Sorin Group, with a 51% stake in MicroPort. Holding. "Based on the absorption of international advanced technology, the joint venture company will develop next-generation pacing technology and products with independent intellectual property rights. It is expected that the new generation of domestic pacemakers will be put on the market in about 5 years, which is much larger than the previous development cycle. compression." It is worth mentioning that the development of high-end medical equipment with independent intellectual property rights is an important part of Shanghai's construction of a global science and technology innovation center. Before the minimally invasive research and development of domestic cardiac pacing, the domestic CT machine and magnetic resonance equipment produced by Shanghai Lianying Medical Technology Co., Ltd. also attracted widespread attention in China. Jiangsu Tiera Biotechnology Co., Ltd , https://www.tierabio.com